[1]
|
Xia, C., Dong, X., Li, H., Cao, M., Sun, D., He, S., et al. (2022) Cancer Statistics in China and United States, 2022: Pro-files, Trends, and Determinants. Chinese Medical Journal, 135, 584-590.
https://doi.org/10.1097/CM9.0000000000002108
|
[2]
|
Petrillo, A., Pompella, L., Tirino, G., Pappalardo, A., Later-za, M.M., Caterino, M., et al. (2019) Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Fu-ture Directions. Cancers, 11, 399.
https://doi.org/10.3390/cancers11030399
|
[3]
|
Li, K., Luo, H., Huang, L., Luo, H. and Zhu, X. (2020) Microsatel-lite Instability: A Review of What the Oncologist Should Know. Cancer Cell International, 20, Article No. 16. https://doi.org/10.1186/s12935-019-1091-8
|
[4]
|
Smyth, E.C., Wotherspoon, A., Peckitt, C., Gonzalez, D., Hulk-ki-Wilson, S., Eltahir, Z., et al. (2017) Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Explora-tory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA On-cology, 3, 1197-1203.
https://doi.org/10.1001/jamaoncol.2016.6762
|
[5]
|
Pietrantonio, F., Randon, G., Di Bartolomeo, M., Luciani, A., Chao, J., et al. (2021) Predictive Role of Microsatellite Instability for PD-1 Blockade in Patients with Advanced Gastric Cancer: A Meta-Analysis of Randomized Clinical Trials. ESMO Open, 6, Article ID: 100036. https://doi.org/10.1016/j.esmoop.2020.100036
|
[6]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomata-ram, I., Jemal, A. and Bray, F. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[7]
|
Green, P.H., O’Toole, K.M., Slonim, D., Wang, T. and Weg, A. (1988) Increasing Incidence and Excellent Survival of Patients with Early Gastric Cancer: Experience in a United States Medical Center. The American Journal of Medicine, 85, 658-661. https://doi.org/10.1016/S0002-9343(88)80238-9
|
[8]
|
Li, P., Huang, C.M., Zheng, C.H., Russo, A., Kasbekar, P., Brennan, M.F., Coit, D.G. and Strong, V.E. (2018) Comparison of Gastric Cancer Survival after R0 Resection in the US and China. Journal of Surgical Oncology, 118, 975-982. https://doi.org/10.1002/jso.25220
|
[9]
|
Glimelius, B., Ekström, K., Hoffman, K., Graf, W., Sjödén, P.O., Haglund, U., et al. (1997) Randomized Comparison between Chemotherapy plus Best Supportive Care with Best Supportive Care in Advanced Gastric Cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 8, 163-168.
https://doi.org/10.1023/A:1008243606668
|
[10]
|
Bang, Y.J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Ran-domised Controlled Trial. The Lancet, 376, 687-697. https://doi.org/10.1016/S0140-6736(10)61121-X
|
[11]
|
Fuchs, C.S., Tomasek, J., Yong, C.J., Dumitru, F., Passalacqua, R., Goswami, C., et al. (2014) Ramucirumab Monotherapy for Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (REGARD): An International, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. The Lancet, 383, 31-39.
https://doi.org/10.1016/S0140-6736(13)61719-5
|
[12]
|
Li, J., Qin, S., Xu, J., Xiong, J., Wu, C., Bai, Y., et al. (2016) Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients with Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 34, 1448-1454. https://doi.org/10.1200/JCO.2015.63.5995
|
[13]
|
梁寒. 中国残胃癌定义的外科专家共识意见(2018年版)解读[J]. 临床外科杂志, 2019, 27(1): 29-31.
|
[14]
|
Zhang, Q.F., Li, J., Jiang, K., Wang, R., Ge, J.L., Yang, H., Liu, S.J., et al. (2020) CDK4/6 Inhibition Promotes Immune Infiltration in Ovarian Cancer and Synergizes with PD-1 Blockade in a B Cell-Dependent Manner. Theranostics, 10, 10619-10633. https://doi.org/10.7150/thno.44871
|
[15]
|
Chao, J., Fuchs, C.S., Shitara, K., Tabernero, J., Muro, K., Van Cutsem, E., et al. (2021) Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncology, 7, 895-902.
https://doi.org/10.1001/jamaoncol.2021.0275
|
[16]
|
Shitara, K., Özgüroğlu, M., Bang, Y.J., Di Bartolomeo, M., Mandalà, M., Ryu, M.H., et al. (2018) Pembrolizumab versus Paclitaxel for Previously Treated, Advanced Gastric or Gastro-Oesophageal Junction Cancer (KEYNOTE-061): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 392, 123-133.
https://doi.org/10.1093/annonc/mdy208.004
|
[17]
|
Shitara, K., Van Cutsem, E., Bang, Y.J., Fuchs, C., Wyrwicz, L., Lee, K.W., et al. (2020) Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-Line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncology, 6, 1571-1580.
https://doi.org/10.1001/jamaoncol.2020.3370
|
[18]
|
Janjigian, Y.Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., et al. (2021) First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 398, 27-40.
https://doi.org/10.1016/S0140-6736(21)00797-2
|
[19]
|
Xu, J., Jiang, H., Pan, Y., Gu, K., Cang, S., Han, L., et al. (2021) LBA53 Sintilimab plus Chemotherapy (Chemo) versus Chemo as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma (ORIENT-16): First Results of a Randomized, Double-Blind, Phase III Study. Annals of Oncology, 32, S1331.
https://doi.org/10.1016/j.annonc.2021.08.2133
|
[20]
|
Accordino, G., Lettieri, S., Bortolotto, C., Benvenuti, S., Gal-lotti, A., Gattoni, E., et al. (2020) From Interconnection between Genes and Microenvironment to Novel Immunothera-peutic Approaches in Upper Gastro-Intestinal Cancers—A Multidisciplinary Perspective. Cancers, 12, Article No. 2105. https://doi.org/10.3390/cancers12082105
|
[21]
|
Li, J., Deng, Y., Zhang, W., Zhou, A.P., Guo, W., Yang, J., et al. (2021) Subcutaneous Envafolimab Monotherapy in Patients with Advanced Defective Mismatch Repair/Microsatellite Instability High Solid Tumors. Journal of Hematology & Oncology, 14, Article No. 95. https://doi.org/10.1186/s13045-021-01095-1
|
[22]
|
Lagergren, J., Lindam, A. and Mason, R.M. (2012) Gastric Stump Cancer after Distal Gastrectomy for Benign Gastric Ulcer in a Population-Based Study. International Journal of Cancer, 131, E1048-E1052.
https://doi.org/10.1002/ijc.27614
|
[23]
|
Hanyu, T., Wakai, A., Ishikawa, T., Ichikawa, H., Kameyama, H. and Wakai, T. (2018) Carcinoma in the Remnant Stomach during Long-Term Follow-Up after Distal Gastrectomy for Gastric Cancer: Analysis of Cumulative Incidence and Associated Risk Factors. World Journal of Surgery, 42, 782-787. https://doi.org/10.1007/s00268-017-4227-9
|
[24]
|
Ramos, M., Pereira, M.A., de Castria, T.B., Ribeiro, R.R.E., Car-dili, L., de Mello, E.S., et al. (2020) Remnant Gastric Cancer: A Neglected Group with High Potential for Immunothera-py. Journal of Cancer Research and Clinical Oncology, 146, 3373-3383. https://doi.org/10.1007/s00432-020-03322-7
|